JPMorgan Chase & Co. Raises TransMedics Group (NASDAQ:TMDX) Price Target to $149.00

TransMedics Group (NASDAQ:TMDX) had its target price boosted by JPMorgan Chase & Co. from $114.00 to $149.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 10.72% from the company’s current price.

TMDX has been the subject of a number of other research reports. Canaccord Genuity Group lifted their price target on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Piper Sandler lifted their target price on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. Needham & Company LLC upped their target price on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research report on Wednesday. Morgan Stanley increased their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group Trading Up 2.1%

NASDAQ:TMDX opened at $134.57 on Wednesday. The company has a market capitalization of $4.62 billion, a P/E ratio of 27.46 and a beta of 2.06. The company has a current ratio of 7.14, a quick ratio of 7.13 and a debt-to-equity ratio of 1.06. TransMedics Group has a 12 month low of $62.07 and a 12 month high of $156.00. The firm has a fifty day simple moving average of $133.45 and a 200-day simple moving average of $126.31.

Insider Buying and Selling

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the sale, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. This trade represents a 5.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Weill sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Whittier Trust Co. of Nevada Inc. grew its position in shares of TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares during the period. Salomon & Ludwin LLC acquired a new position in shares of TransMedics Group during the 3rd quarter worth about $28,000. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group in the 3rd quarter valued at about $29,000. Optiver Holding B.V. boosted its holdings in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after buying an additional 191 shares during the last quarter. Finally, Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Q4 results beat expectations — Q4 EPS of $0.57 and ~32% revenue growth topped estimates; management raised 2026 revenue guidance to roughly 20–25%, supporting near‑term top‑line momentum. TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates
• Positive Sentiment: Analysts raised targets and ratings — Several firms bumped price targets (Oppenheimer to $175/outperform; Needham to $174/buy; Piper Sandler to $160/overweight; JPMorgan to $149/neutral), signaling institutional confidence in the company’s growth trajectory and helping push the stock higher. TransMedics Group (NASDAQ:TMDX) Given New $175.00 Price Target at Oppenheimer TransMedics Group (NASDAQ:TMDX) Given New $174.00 Price Target at Needham & Company LLC TransMedics Group (NASDAQ:TMDX) Given New $160.00 Price Target at Piper Sandler TransMedics Group (NASDAQ:TMDX) Given New $149.00 Price Target at JPMorgan Chase & Co.
• Positive Sentiment: Visibility on growth initiatives — Management highlighted advancing OCS (organ care system) programs and European expansion as drivers of the 20–25% 2026 revenue target, giving investors a clearer multi‑year growth story. TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
• Neutral Sentiment: Earnings materials and call available — The company released its Q4 presentation and the full earnings‑call transcript, useful for parsing unit trends, margins, and cadence of commercialization. TransMedics Group, Inc. 2025 Q4 – Results – Earnings Call Presentation TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Investor commentary and outlook pieces are circulating — Market write‑ups are debating whether the strong one‑year +79% move leaves room for more upside or signals late‑cycle profit taking. Is It Too Late To Consider TransMedics Group (TMDX) After Its 79% One-Year Surge?
• Negative Sentiment: Valuation and momentum risk — The stock’s run and a P/E near the mid‑20s leave vulnerability to multiple contraction or profit‑taking if execution or cadence disappoints; investors should weigh growth guidance against elevated expectations.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.